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Background: Pirfenidone was recently approved for treatment of idiopathic pulmonary fibrosis. However, the
therapeutic dose of pirfenidone is very high, causing side effects that limit its doses and therapeutic effectiveness.
Understanding the molecular mechanisms of action of pirfenidone could improve its safety and efficacy. Because
activated fibroblasts are critical effector cells associated with the progression of fibrosis, this study investigated the
genes that change expression rapidly in response to pirfenidone treatment of pulmonary fibroblasts and explored
their contributions to the anti-fibrotic effects of pirfenidone.
Methods: We used the GeneChip microarray to screen for genes that were rapidly up-regulated upon exposure of
human lung fibroblast cells to pirfenidone, with confirmation for specific genes by real-time PCR and western blots.
Biochemical and functional analyses were used to establish their anti-fibrotic effects in cellular and animal models
of pulmonary fibrosis.
Results: We identified Regulator of G-protein Signaling 2 (RGS2) as an early pirfenidone-induced gene. Treatment
with pirfenidone significantly increased RGS2 mRNA and protein expression in both a human fetal lung fibroblast
cell line and primary pulmonary fibroblasts isolated from patients without or with idiopathic pulmonary fibrosis.
Pirfenidone treatment or direct overexpression of recombinant RGS2 in human lung fibroblasts inhibited the profibrotic
effects of thrombin, whereas loss of RGS2 exacerbated bleomycin-induced pulmonary fibrosis and mortality in mice.
Pirfenidone treatment reduced bleomycin-induced pulmonary fibrosis in wild-type but not RGS2 knockout mice.
Conclusions: Endogenous RGS2 exhibits anti-fibrotic functions. Upregulated RGS2 contributes significantly to
the anti-fibrotic effects of pirfenidone.
Keywords: RGS2, Pirfenidone, Bleomycin, Early response genes, Human fetal lung fibroblasts, Primary human
pulmonary fibroblasts, Proliferation, Fibroblast to myofibroblast differentiation, Knockout, Idiopathic pulmonary
fibrosisBackground
Idiopathic pulmonary fibrosis (IPF) is a chronic and
ultimately fatal disease characterized by a progressive
decline in lung function [1, 2]. In the US, IPF affects
over 150,000 people, and 40,000 patients die from IPF
each year [3, 4]. It is widely thought that IPF causes loss* Correspondence: tbcasale@health.usf.edu; Yat6033@creighton.edu
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myofibroblasts that in turn result in collagen deposition
and fibrosis. These changes cause disruption of the gas per-
meability barrier and stiffen lung tissue, thereby impairing
ventilation of nearby normal lung tissue [1, 5, 6]. IPF pa-
tients eventually experience dyspnea at rest and, without a
lung transplant, have a 5-year average survival rate of only
20 % [3, 4].
A wide range of therapies have failed in IPF clinical trials
[7, 8]. Pirfenidone (PFD) is an orally administered small
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tion in IPF and was recently approved by the U.S. Food
and Drug Administration (FDA) to treat IPF [13–16].
Unfortunately, the therapeutically effective dose of PFD is
very high (>30 mg/kg, daily) [17, 18], which can cause
significant side effects such as gastro-esophageal reflux,
phototoxicity, dizziness, and fatigue, thereby limiting its
therapeutic effectiveness [16]. Understanding the molecular
mechanisms that contribute to PFD effects could improve
its safety and efficacy. Activated fibroblasts/myofibro-
blasts are key pathological features of IPF and are crit-
ical effector cells associated with the progression of
fibrosis [5, 6, 19, 20]. Several studies have indicated that
PFD reduces growth factor-driven fibroblast proliferation,
differentiation, and extracellular matrix production [10, 21].
However, the specific molecular mechanisms whereby PFD
produce these diverse effects to achieve its clinical benefits
in IPF remain unknown [15].
In the studies presented here, we used the GeneChip
microarray method to identify RGS2 as an early response
gene elevated in response to PFD treatment of human lung
fibroblast cells. RGS2 selectively inhibits the magnitude
and duration of Gq protein-coupled receptor-induced sig-
naling [22–24]. G protein-coupled receptors (GPCRs) have
been shown to play important roles in the pathogenesis of
chronic lung diseases including IPF [25–28]. There is also
evidence that RGS2 is functionally important in regulating
the pathogenesis of fibrosis. For example, RGS2 was found
to inhibit the progression of kidney fibrosis following uni-
lateral ureteral obstruction in mice [29]. We recently found
that mice lacking RGS2 exhibit increased peribronchial
fibrosis in an acute mouse model of asthma induced by
administration of intranasal interleukin 13 (5 μg/day) for
3 days [30]. However, the role of RGS2 in the onset and
progression of IPF remains unknown. Using cellular and
animal models, we demonstrate here that endogenous
RGS2 exhibits anti-fibrotic functions and that early upreg-




PFD (5-methyl-1-phenyl-2-(1H)-pyridone) and human
thrombin were purchased from Sigma-Aldrich (St. Louis,
MO). Unless indicated otherwise, all other reagents were
from Sigma-Aldrich or Thermo Fisher Scientific (Waltham,
MA). The human fetal lung fibroblast cell line (HFL1) was
purchased from ATCC (CCL-153™, Manassas, VA). Primary
human lung fibroblasts were isolated and cultured from
lung tissues obtained during open lung biopsy from pa-
tients who were undergoing lung transplantation or at time
of death. Control primary human lung fibroblast (CPHLF)
cell lines were established by Dr. Reynold Panettieri’s lab
(University of Pennsylvania) from three patients with brain-related disease but no history of pulmonary fibrosis. Dis-
eased primary human lung fibroblast (DPHLF) cell lines
were established by Dr. Carol Feghali-Bostwick (Medical
University of South Carolina) [31, 32] from two patients
with IPF who had a confirmed diagnosis based on the
criteria established by the American Thoracic Society. The
biopsies had no identifiers, and the protocols for cell isola-
tion were approved by the respective universities’ Institu-
tional Review Boards.
Cell culture and drug treatments
Cells were routinely cultured at 37 °C with 5 % CO2 in
1:1 mixture of Dulbecco's Modified Eagle's Medium
(DMEM) and Ham's F-12 Nutrient Mixture (F12) sup-
plemented with 10 % FBS and were used at passage <10
for experiments. For dose–response experiments, human
lung fibroblast cells were seeded into 12-well plates,
starved in serum-free DMEM/F12 medium for 24 h, and
then treated with the indicated concentrations of PFD
for the indicated times.
Quantitative PCR
Total RNA extraction and quantitative real-time PCR
were conducted as described previously [33]. The RNA
samples were treated with DNase I (Thermo Scientific,
Waltham, MA) to remove contaminating genomic DNA
prior to experiments. The housekeeping gene β-actin
plasmid was purchased from ATCC (MGC-10559).
Human RGS2 was constructed into pcDNA3.1 (Invitro-
gen Life Technology) [30]. For RGS2, standard curves
were generated by plotting the threshold cycle (CT)
against the natural log of the copy number of plasmid
molecules. The equations from the graphs were used to
calculate the copy numbers of cDNA molecules present
in the unknown samples based on the corresponding CT
values. For connective tissue growth factor (CTGF),
standard curves were generated by plotting the CT
against serial dilutions of sample. The primers for CTGF
were: 5’-CAGCATGAAGACATACCGAGC-3’ and 5’-
GACAGTTGTAATGGCAGGCAC-3’.
GeneChip microarray
Total RNA of control and PFD-treated HFL1 cells pooled
from three individual experiments were analyzed by the
Genome Sequencing Facility, University of Kansas Med-
ical Center using Human Gene 2.0 ST Arrays (Affymetrix,
Santa Clara, CA) and standard Affymetrix protocols [34].
GeneChip microarray analysis was replicated with two dif-
ferent pooled samples and the results were expressed as
the ratio of PFD-treated vs. vehicle control.
Western blot analysis
Cell protein extraction and western blot were conducted
as described previously [30, 35]. Protein was extracted
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TX). Samples were electrophoresed and subjected to
western blot using primary antibodies against RGS2
(Proteintech, Chicago, IL) and β-actin. IRDye-800 sec-
ondary antibodies (LI-COR, Lincoln, NE) were used to
capture images with a LI-COR Odyssey.
Overexpression of recombinant RGS2 in HFL1 cells
The medium of HFL1 cells (50 % confluence) was replaced
with growth medium containing human Adenovirus Type5
expressing RGS2 under the ubiquitin C promoter with co-
expression of an mCherry reporter under a separate cyto-
megalovirus promoter (Ad-RGS2/mCherry) (SignaGen
Laboratories, Rockville, MD) at a multiplicity of infection
of 50 plaque-forming units. Cells infected with adenovirus
expressing mCherry reporter (Ad-mCherry) were used as a
control. The cells were incubated for 24 h at 37 °C and re-
seeded for various experiments.
Measurement of intracellular Ca2+ ([Ca2+]i)
HFL1 cells seeded into 96-well plates at 1 × 105cells/well
were cultured in serum-free medium for 24 h. Thrombin-
induced changes in intracellular Ca2+ concentration were
measured with the Fluo-8 No Wash Calcium Assay kit
(Abcam, Cambridge, MA) according to kit instructions.
The plates were transferred to a FLEX Station II benchtop
scanning fluorometer chamber (Molecular Devices, Sun-
nyvale, CA). The cells were excited at 490 nm and Ca2
+-bound fluo-8 emission was recorded at 525 nm. The
fluo-8 fluorescence was expressed as Fmax/F0 where Fmax
was the maximum and F0 was the baseline fluorescence
measured.
Cell proliferation assay
HFL1 cells were treated with thrombin (1 U/ml, Sigma-
Aldrich, St. Louis, MO) for 6 h and then labeled with
10 μM 5-bromo-2’-deoxyuridine (BrdU) (BD Pharmigen,
San Jose, CA) for 18 h. Cells were stained for nuclei and
BrdU using 4’,6-diamidino-2-phenylindole (DAPI) and
anti-BrdU antibody (Cell Signaling, Danvers, MA) [36].
Results are expressed as the percentage of DAPI-stained
cells that were also BrdU-positive.
Immunofluorescence staining for α-smooth muscle actin
HFL1 cell α-smooth muscle actin (α-SMA) was visual-
ized with an anti-α-actin primary antibody and an Alexa
Fluor 488-labeled secondary antibody [37]. The results
are expressed as the percentage of DAPI-stained cells
that also have clear α-SMA–positive stress fibers.
Gel contraction assay
HFL1 cells (2.5×105 cells/ml) were suspended in type I
collagen from rat tail tendon (1.25 mg/ml, BD Bioscience,
Bedford, MA). The collagen-cell suspension was added to24-well plates (300 μl /well) and allowed to polymerize for
45 min at 37 °C. After incubating with DMEM containing
10 % fetal bovine serum (FBS) for 4 h, the medium from
the polymerized gels was changed to serum-free medium.
Polymerized gels were incubated overnight and were then
stimulated with thrombin (1 U/ml) for 24 h. To initiate
collagen gel contraction, polymerized gels were gently
released from the underlying culture plate and digitally
photographed. The gel areas were analyzed using Image-
Pro Plus 6.0 (Media Cybernetics, Rockville, MD) and
expressed as arbitrary area units [37].
Measurement of collagen production and deposition
The amount of lung collagen was measured using a Sirius
red total collagen detection kit (Chondrex, Redmond,
WA) as described [38]. Briefly, to determine collagen pro-
duction from fibroblasts in vitro, HFL1 cells seeded into
6-well plates (5 × 105cells/well) were starved for 24 h and
then stimulated with 1 U/ml thrombin for another 24 h.
Cells were harvested and the amount of collagen in cell
lysates was determined. To measure collagen deposition
in vivo, mouse lung tissues were minced and subjected to
the same analysis of the amount of collagen [30].
Bleomycin-induced mouse pulmonary fibrosis and
inhalation delivery of PFD
All animal studies were approved by the Institutional
Animal Care and Use Committee at Creighton University.
Age- (~11 weeks) and weight- (~20 g) matched RGS2
wild-type (+/+) and knockout (−/−) C57BL/6 J mice [39]
were obtained by in-house breeding and are descendants
from the original breeding pairs provided by the Univer-
sity of Texas Southwestern Medical Center with approval
from the originator, Dr. David Siderovski (West Virginia
University).
Anesthetized mice were administered a single dose of
bleomycin sulfate dissolved in 0.9 % saline by intratra-
cheal instillation with an IA-1C MicroSprayer aerosoli-
zer (PennCentury, Wyndmoor, PA) to induce pulmonary
fibrosis [18, 40]. Pulmonary fibrosis was evaluated
21 days later. A lower dose of bleomycin (1.0 U/kg body
weight) was used for comparing alterations in lung func-
tion and histology between RGS2+/+ and RGS2−/−
mice. To compare long-term survival rates, 2.0 U/kg of
bleomycin was administered.
To examine therapeutic effects of PFD, mice were
administrated bleomycin (1.5 U/kg body weight) as de-
scribed above and divided into four groups (4 mice/
group): bleomycin in RGS2+/+, bleomycin + PFD in RGS2
+/+, bleomycin in RGS2−/−, bleomycin + PFD in RGS2
−/−. One week after bleomycin administration, PFD solu-
tion was administered using a nose-only aerosol exposure
tower (Data Sciences International, St. Paul, MN). Aerosol
was delivered with the Aeroneb Lab Micropump
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0.4 ml of aerosolized 5 mM PFD or saline (vehicle control)
for 14 successive days. Actual administered doses were
calculated according to the following formulas [41]:
Estimation of inhaled volume per mouse V1ð Þ
¼ N=VAð Þ  TV  RR  T
Estimation of PFD administered dose D
¼ C  V1ð Þ=W
In these formulas, N is nebulization rate (300 ml/min),
VA is air flow (0.2 L/min), TV is tidal volume (estimated
at 170 ml), RR is respiratory rate (estimated at 150
breaths/min), T is the duration of treatment, C is PFD
concentration (926 mg/L), and W is mouse weight.
Based on these parameters, the estimated administered
dose was 0.35 mg PFD/kg daily.
Mouse lung function analysis
Mouse lung dynamic compliance (Cdyn) was recorded
using a FinePointe system (Buxco, St. Paul, MN) as pre-
viously described [30, 35].
Histologic analysis
Sections of paraformaldehyde-fixed mouse lungs were
analyzed by hematoxylin and eosin (H&E) or Masson’s
trichrome staining to assess fibrotic changes in the lungs
[30, 42]. Photos of 20 fields from multiple sections of
each mouse were taken at 100X magnification and
scored separately by the modified Ashcroft method
(score range 0–8) [43, 44]. The pulmonary fibrosis histo-
pathology score of each mouse is expressed as the mean
score of 20 photos.
Statistical analysis
Data are expressed as means ± SEM. Groups were com-
pared using Student’s t test for unpaired observations or
two-way ANOVA with the Bonferroni correction for
multiple comparisons. p < 0.05 was taken as statistically
significant.
Results
RGS2 is an early response gene elevated by PFD
treatment of HFL1 cells
The transcriptome profiles of control versus PFD-
treated HFL1 cells were determined by GeneChip
microarray analysis. This analysis of 48,226 human
transcripts revealed 76 genes that were upregulated by
at least 2-fold within the first 2 h of treatment with
10 mM PFD (Additional file 1: Table S1). The 10 most
highly upregulated genes are presented in Fig. 1a. RGS2
was among the top six genes, with a 6-fold upregulation
after PFD treatment. Interestingly, RGS2 was the onlyone among 21 members of the RGS gene family to be
significantly upregulated in HFL1 cells (Fig. 1b).
Because of our prior work and strong interest in RGS
proteins, our further studies focused only on RGS2.
RGS2 mRNA and protein expression levels are increased
by PFD in HFL1 and primary human lung fibroblast cells
Quantitative RT-PCR analysis confirmed that 10 mM PFD
treatment increased RGS2 mRNA levels in HFL1 cells and
three control primary human lung fibroblast (CPHLF) cell
lines (Fig. 1c). As expected, western blots confirmed that
PFD treatment for 2 h also increased RGS2 protein levels
in these fibroblast cells by 3.5-fold (Fig. 1d). We also inves-
tigated whether PFD induced RGS2 expression in diseased
primary human lung fibroblast (DPHLF) cell lines estab-
lished from patients with IPF. As shown in Fig. 1e, treat-
ment with 10 mM PFD increased RGS2 mRNA and
protein levels by 4- and 3-fold, respectively (Fig. 1e and
inset). Quantitative RT-PCR analysis of HFL1 cells showed
that RGS2 mRNA induction by PFD occurred in a
concentration-dependent manner (Fig. 1f) and achieved
statistical significance at concentrations of 5 and 10 mM
(p < 0.05); 10 mM PFD caused a 6-fold induction of RGS2
mRNA. RGS2 mRNA induction occurred at all time points
tested from 1 to 18 h after 10 mM PFD treatment; peak
levels of 6-fold were seen 2 h after treatment and gradually
declined, with 2.5-fold upregulation at 18 h (Fig. 1g).
RGS2 protein attenuates thrombin-induced increase of
[Ca2+]i in HFL1 cells
The serine protease thrombin activates Gq-coupled
proteinase-activated receptor 1 (PAR1) to promote fibro-
blast proliferation and differentiation into a myofibroblast
phenotype, contributing to development of pulmonary
fibrosis [28, 37]. Previous studies have shown that throm-
bin stimulation of proliferation is dependent on PAR1-
mediated increase of [Ca2+]i in many cell types [45, 46]. Be-
cause RGS2 functions as a selective modulator of Gq-medi-
ated signaling [22–24], the effects of RGS2 expression on
thrombin-induced increases of [Ca2+]i in HFL1 cells were
examined. RGS2 protein was increased by about 6-fold in
HFL1 cells with adenovirus-expressing RGS2 and mCherry
reporter in comparison to control cells with the mCherry-
expressing adenovirus alone (Fig. 2a). Thrombin induced a
dose-dependent increase of [Ca2+]i in the mCherry-alone
control HFL1 cells (Fig. 2b). As compared with these con-
trol cells, overexpression of RGS2 significantly attenuated
the thrombin (1 U/ml)-induced increase in [Ca2+]i in HFL1
cells from 3.75 ± 0.07 to 2.31 ± 0.05 (Fig. 2c, p < 0.01).
RGS2 protein inhibits thrombin-induced proliferation of
HFL1 cells
We next investigated whether increases in RGS2
expression functionally attenuate thrombin-stimulated
Fig. 1 Identification of RGS2 as an early response gene to PFD treatment in human lung fibroblasts. Genechip microarray revealed PFD–induced
upregulated genes, with the top ten shown (a) and selective upregulation of RGS2 in the RGS gene family in human fetal lung fibroblast (HFL1)
cells (b). Data shown are the means of two Genechip microarray assays using different pooled total RNA. The results are expressed as the fold
change calculated as the ratio of the two groups. HFL1, three control primary human lung fibroblast (CPHLF1-3) (c and d), and two diseased primary
human lung fibroblast (DPHLF1-2) (e) cell lines were treated with saline (control) or 10 mM PFD for 2 h and then processed for real-time PCR (c, e) and
western blot analyses (d, e). The results of real-time PCR were normalized as RGS2/β-actin × 1000 and plotted as means ± SEM (n = 4). A blot
representative of three experiments is shown (d and e, insets). Mean RGS2 band density was normalized to β-actin ± SEM. HFL1 cells were
treated with various concentrations of PFD (0–10 mM) for 2 h (f) or with 10 mM PFD over a time course of 18 h (g). Cells were harvested for
real-time PCR analysis of RGS2 and β-actin mRNA levels. The results are shown as means ± SEM (n = 4). * p < 0.05, ** p < 0.01 vs. control
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that the proliferation rate (% BrdU-positive cells) in
control HFL1 cells was increased from a basal level of
5.6 ± 0.9 % to 25.3 ± 2.2 % (p < 0.01) following thrombin
(1 U/ml) treatment for 24 h (Fig. 3a). In contrast, thebasal proliferation rate of HFL1 cells overexpressing
RGS2 and mCherry was 4.1 ± 1.1 % and this value was
increased to 7.6 ± 1.8 % by thrombin (Fig. 3a). Thus,
overexpression of RGS2 attenuated the thrombin-
stimulated cell proliferation by about 70 % (p < 0.01).
Fig. 2 Increase of RGS2 attenuates thrombin-induced increase of [Ca2+]i in HFL1 cells. HFL1 cells were infected with Ad-mCherry or Ad-RGS2/
mCherry for 24 h. a RGS2 and mCherry expression was assessed by western blots (left panel) and fluorescence microscopy (right panel),
respectively. Infection efficiency was approximately 90 % based on the percentage of cells expressing mCherry (scale bar = 50 μm). b
Thrombin induced a dose-dependent increase of [Ca2+]i in un-infected HFL1 cells. c Thrombin-induced [Ca
2+]i increase in HFL1 cells
infected with Ad-mCherry or Ad-RGS2/mCherry. Cells pre-loaded with Fluo-8 were stimulated with various concentrations of thrombin (0.1–2 U/ml) (b)
or 1 U/ml of thrombin (c). The increase of Fluo-8 fluorescence from four experiments is plotted as means ± SEM. ** p < 0.01 as compared to control
untreated cells
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HFL1 cells
Fibroblasts treated with thrombin acquire a more con-
tractile phenotype characterized by elevated α-SMA
[34]. As shown in Fig. 3b (left panel), HFL1 cells treated
with thrombin displayed abundant stress fibers that
stained intensely for α-SMA. The percentage of α-SMA
staining-positive HFL1 cells was significantly increased
in both mCherry alone and mCherry plus RGS2 cells
after stimulation for 24 h with thrombin. However, over-
expression of RGS2 attenuated the thrombin-stimulated
increase in α-SMA expression-positive cells by about
half (14.0 ± 1.6 % vs. 27.6 ± 3.2 %; Fig. 3b, right, p < 0.05).
Collagen gel contraction assays demonstrated that RGS2
attenuation of α-SMA expression has functional conse-
quences. Thrombin stimulation of HFL1 cells expressing
mCherry caused a 73 % reduction in gel size as compared
to a less than 30 % reduction in gel size when HFL1 cells
expressing RGS2 and mCherry were stimulated with
thrombin (Fig. 3c). As expected, treatment with 1 U/ml of
thrombin for 24 h increased collagen production in HFL1
cells, by 2.2-fold (0.68 ± 0.07 vs. 1.47 ± 0.14 μg per 105 cells,
p < 0.01). Overexpression of RGS2 reduced basal collagen
production by about 20 % but significantly attenuatedthrombin-stimulated collagen production in HFL1 cells by
about half (0.78 ± 0.10 vs. 1.47 ± 0.14, p < 0.01) (Fig. 3d).
RGS2 protein attenuates thrombin-stimulated CTGF
mRNA expression in HFL1 cells
CTGF is an important mediator of fibrosis [47, 48]. A pre-
vious study showed that stimulation with thrombin rapidly
induced CTGF expression that in turn increased extracellu-
lar matrix protein production in lung fibroblasts [49]. As
shown in Fig. 3e, treatment with thrombin (1 U/ml) for 3 h
caused a significant increase in CTGF mRNA levels in
HFL1 cells transfected with mCherry (3.2 ± 0.41 vs. 1.1 ±
0.12, p < 0.01). Overexpression of RGS2 slightly reduced
basal CTGF mRNA expression but significantly attenuated
the thrombin-stimulated increase of CTGF mRNA expres-
sion by more than 50 % (1.4 ± 0.15 vs. 3.2 ± 0.41, p < 0.01).
Treatment with PFD inhibits the profibrotic effects of
thrombin in HFL1 cells
Since PFD treatment induces RGS2 expression in human
lung fibroblast, we next investigated whether PFD treat-
ment also inhibits the profibrotic effects of thrombin. As
shown in Fig. 4a (inset), treatment with 5 mM PFD
increased RGS2 protein expression by 4-fold in HFL1 cells.
Fig. 3 RGS2 suppresses the profibrotic effects of thrombin in HFL1 cells. HFL1 cells were infected with Ad-mCherry or Ad-RGS2/mCherry for 24 h.
Cells were then treated without or with thrombin (1 U/ml) for 24 h. a HFL1 cell proliferation was assessed by BrdU incorporation assays. Left panel:
representative staining images of BrdU (green) incorporation and DAPI (blue) indicated the location of nuclei under immunofluorescence microscopy
(scale bar = 50 μm). Right panel: quantitative analysis for each treatment was performed by counting the percentage of DAPI-stained cells that were
also BrdU-positive. Data are means ± SEM from at least 100 fibroblast cells. b HFL1 cell differentiation was assessed by immunofluorescence staining for α-
SMA. Left panel: representative staining images of α-SMA (green) and DAPI (blue) indicated the location of nuclei under immunofluorescence microscopy
(scale bar = 50 μm). Right panel: The results are expressed as the percentage of total DAPI-stained cells that also had clear α-SMA–positive stress fibers. Data
are means ± SEM from at least 100 fibroblast cells. c HFL1 cell contraction was assessed by collagen gel contraction assays. Top: Images of collagen gels
containing 2.5×105 cells/ml without and with thrombin stimulation for 24 h. Bottom: Results are expressed as the mean gel area ± SEM from at least three
separate experiments. d The amount of collagen in HLF1 cell lysates was measured by the Sirius red collagen assay. Results are expressed as μg of collagen
per 105 cells. Data are means ± SEM (n= 3). e HFL1 cells infected with Ad-mCherry or Ad-RGS2/mCherry were treated without or with 1 U/ml of thrombin
for 3 h and then processed for real-time PCR. The results of real-time PCR were normalized as CTGF/β-actin and plotted as means ± SEM (n= 3). * p< 0.05,
** p< 0.01 between groups
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HFL1 cells pretreated with PFD was significantly lower than
that in cells pretreated with vehicle control (2.53 ± 0.15 vs.3.72 ± 0.14, p < 0.05) (Fig. 4a). Thrombin significantly
increased cell proliferation from 7.8 ± 1.7 % to 18.3 ± 2.0 %
(p < 0.01) in control HFL1 cells. PFD treatment decreased
Fig. 4 PFD treatment inhibits the profibrotic effects of thrombin in HFL1 cells. Cells were treated with vehicle control or 5 mM PFD for 24 h. a
Thrombin (1 U/ml)-induced increase of [Ca2+]i in control and PFD-treated HFL1 cells. The increase of Fluo-8 fluorescence from four experiments is plotted
as means ± SEM. A representative western blot of RGS2 protein expression from three experiments is shown (a, inset). b HFL1 cell proliferation. Data are
means ± SEM from at least 100 fibroblast cells. c HFL1 cell differentiation. Left panel: representative staining images of α-SMA (green) and DAPI (blue) (scale
bar = 50 μm). Right panel: The results are expressed as the percentage of total DAPI-stained cells that also had clear α-SMA–positive stress fibers. Data are
means ± SEM from at least 100 fibroblast cells. d HFL1 cell contraction. Top: Images of collagen gels containing 2.5×105 cells/ml without and
with thrombin stimulation for 24 h. Bottom: Results are expressed as the mean gel area ± SEM from at least three separate experiments. e The
amount of collagen in HLF1 cell lysates. Data are means ± SEM (n = 3). f Treatment of PFD abolished thrombin-induced CTGF mRNA expression
in HFL1 cells. Data were normalized as CTGF/β-actin and plotted as means ± SEM (n = 3). * p < 0.05, ** p < 0.01
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bin stimulation of HFL1 cell proliferation (Fig. 4b). It
should be noted that PFD inhibition of cell proliferation
was not due to cytotoxicity because trypan blue staining of
cells showed no significant changes in cell viability with
PFD treatment (data not shown).
We also investigated the effect of PFD treatment on
thrombin-induced differentiation of HFL1 cells. As shownin Fig. 4c, thrombin treatment increased the percentage of
α-SMA staining-positive cells in vehicle-treated control
HFL1 cells by about 17-fold, from 2.2 ± 0.8 % to 36.6 ±
5.0 %, as compared to 3.5-fold increase (from 1.7 ± 0.4 %
to 6.2 ± 0.9 %) in cells pre-treated with 5 mM PFD. Thus,
the stimulatory effect of thrombin was largely attenuated
by PFD treatment. In collagen gel contraction assays,
thrombin stimulation of HLF1 cells caused a 54 %
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with PFD did not contract at all (Fig. 4d). Consistent with
the results for differentiation, increased levels of collagen
production (Fig. 4e) and CTGF mRNA expression (Fig. 4f)
were detected when HFL1 cells were stimulated with
thrombin, and these increases were largely abolished by
PFD treatment. Thus, PDF treatment inhibits the profi-
brotic effects of thrombin in HFL1 cells.
Loss of RGS2 augments the development of bleomycin-
induced pulmonary fibrosis in mice
The mouse bleomycin-induced lung fibrosis model has
been widely used to explore both the pathogenesis of IPF
and potential new therapies [18, 39]. We used this model to
investigate the importance of RGS2 in regulation of the
pathogenesis of IPF. RGS2 wild-type (+/+) and RGS2
knockout (−/−) mice (12 per group) were administered a
high intratracheal dose of bleomycin (2 U/kg body weight)
(Fig. 5a). By 21 days after exposure, 3 of the RGS2+/+ mice
and 8 of the RGS2−/− mice had died. The Mantel-Cox log
rank test showed that the survival rate of the RGS2−/−
mice was significantly shorter than that of the RGS2+/+
mice (p = 0.03) (Fig. 5b).
Next, a lower bleomycin dose (1 U/kg) or saline con-
trol was instilled intratracheally into RGS2+/+ and RGS2
−/− mice; this dose did not cause any mortality in either
group. Dynamic lung compliance (inverse of lung stiff-
ness) of these mice measured on Day 22 was signifi-
cantly lower in control RGS2−/− mice compared with
control RGS2+/+ mice (0.024 ± 0.001 vs. 0.032 ± 0.001,
p < 0.01). Bleomycin induced a significant loss of lung
compliance in both RGS2+/+ (0.026 ± 0.001 vs. 0.032 ±
0.001, p < 0.01) and RGS2−/− mice (0.015 ± 0.002 vs.
0.024 ± 0.001, p < 0.01). However, the loss in lung com-
pliance caused by bleomycin treatment was 2 times
greater in RGS2 −/− mice (38 %) than in RGS2+/+ mice
(19 %) (Fig. 5c).
Histochemical staining with trichrome indicated that
bleomycin administration induced deposition of collagen
in both RGS2+/+ and RGS2−/− mice (Fig. 5d), but the
collagen deposition was greater and its overall distribu-
tion was more widespread in RGS2−/− mice. Scoring the
bleomycin-induced histological fibrosis by the Ashcroft
method confirmed that pulmonary fibrosis was signifi-
cantly increased in RGS2−/− mice as compared with
RGS2+/+ mice (4.80 ± 0.15 vs. 3.53 ± 0.14, n = 5, p <
0.01) (Fig. 5e). Total lung collagen assays showed nearly
two-fold increased basal levels of collagen in RGS2−/−
mice when compared with RGS2+/+ mice (93.0 ± 8.2 vs.
45.3 ± 3.6 μg per 100 mg of lung tissue, p < 0.01), and
bleomycin treatment further increased the RGS2−/−
lung collagen to 380.6 ± 12.7 μg, more than three times
higher than that in bleomycin-treated RGS2+/+ mice
(129.2 ± 10.5 μg) (p < 0.01) (Fig. 5f ).Local delivery of PFD ameliorates bleomycin-induced pul-
monary fibrosis in RGS2+/+ but not in RGS2−/− mice
We next tested the effectiveness of PFD to reduce
bleomycin-induced fibrosis. One week after intratracheal
administration of 1.5 U/kg bleomycin, mice were treated
daily for 2 weeks with saline vehicle or PFD (0.35 mg/
kg) via nose-only aerosolized delivery (Fig. 6a). Western
blots showed that PFD treatment increased RGS2
expression in the lungs of RGS2+/+ mice, whereas no
RGS2 protein was detected in RGS2−/− mice (Fig. 6b).
In addition, RGS2+/+ mice treated with PFD exhibited
significantly higher lung compliance than mice treated
with vehicle (0.023 ± 0.001 vs. 0.014 ± 0.001, p < 0.01)
(Fig. 6c), indicating that the bleomycin-induced loss of
lung compliance was attenuated by PFD treatment. Ad-
ministration of PFD also ameliorated the fibrotic lung le-
sions induced by bleomycin in RGS2+/+ mice, as shown
by trichrome staining of collagen deposition (Fig. 6d).
The Ashcroft score in bleomycin-treated RGS2+/+ mice
was significantly reduced by PFD treatment, from 4.90 ±
0.09 to 3.62 ± 0.19 (Fig. 6e, p < 0.01). The collagen levels
in the lungs of bleomycin-treated RGS2 +/+ mice were
decreased by 60 % (n = 4, p < 0.01) (Fig. 6f ). In contrast,
in RGS2−/− mice, the bleomycin-induced changes in
lung compliance and deposition of collagen were un-
affected by PFD treatment (Fig. 6c–f ). Thus, the elevated
RGS2 expression induced by PFD treatment is crucial
for PFD protection of mice against bleomycin-induced
pulmonary fibrosis.
Discussion
Although PFD is approved by the FDA for treatment of
IPF, its cellular targets and molecular mechanisms of ac-
tion remain poorly understood. In the present study, we
took the novel approach of screening for genes whose
expression changed rapidly upon exposure of HFL1 cells
to PFD. This screen identified RGS2 as one of the genes
most highly upregulated in response to short-term PFD
treatment. Quantitative RT-PCR and western blot ana-
lyses confirmed PFD induction of RGS2 expression in
five other primary human lung fibroblast cell lines iso-
lated from patients without or with IPF, confirming that
this is a general phenomenon. This induction of RGS2
expression is a previously unrecognized genomic re-
sponse to PFD, and our further studies strongly suggest
that RGS2 upregulation is a significant contributor to
the pulmonary fibrosis protection induced by PFD.
RGS2 inhibits both the amplitude and duration of sig-
nals mediated by Gq-coupled GPCRs [21–23]. Interest-
ingly, several Gq-coupled GPCRs and their ligands are
important drivers of pulmonary fibrosis, including PAR1,
lysophosphatidic acid receptor 1, and endothelin receptors
[25–28]. Inhibition of these signals by RGS2 that is upreg-
ulated in response to PFD thus provides a mechanistic
Fig. 5 Loss of RGS2 arguments the development of bleomycin-induced pulmonary fibrosis in mice. a Outline of experimental design. On Day 1,
bleomycin was administrated intratracheally into RGS2+/+ and RGS2−/− mice. On Day 22, dynamic lung compliance of mice was measured. b
Loss of RGS2 augments the death rate in bleomycin (2 U/kg body weight)-induced mouse pulmonary fibrosis model. Kaplan-Meier survival curves were
created for bleomycin-exposed RGS2+/+ and RGS2−/− mice (n = 12 per group). c Effects of bleomycin (1 U/kg) on dynamic lung compliance (Cdyn) of
RGS2+/+ and RGS2−/− mice. d The lungs were stained with trichrome to visualize collagen deposition (blue). Representative sections from each group
are shown (scale bar = 200 μm). e Sections were scored by the modified Ashcroft method for overall fibrosis. Results are shown as means ± SEM (n = 5)
and were analyzed using a two-sided t-test. f Total lung collagen content was measured by the Sirius red collagen assay. Results are expressed as μg
of collagen per 100 mg of lung tissue. Data are means ± SEM (n = 5 mice). ** p < 0.01
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in terms of reducing fibrotic responses of lung fibroblasts.
Indeed, when HFL1 cells were exposed to thrombin, a
protease elevated in bronchial alveolar lavage fluid of IPF
patients [50], PFD treatment or direct overexpression of
recombinant RGS2 to levels similar to those induced byPFD treatment can trigger several anti-fibrotic responses
in HFL1 cells. For example, PFD treatment or overexpres-
sion of RGS2 suppressed thrombin-induced proliferation
and differentiation of HFL1 cells, key components of IPF
[37]. Thrombin-induced collagen production, CTGF ex-
pression, and gel contraction were also inhibited by PFD
Fig. 6 PFD ameliorates bleomycin-induced pulmonary fibrosis in RGS2+/+ but RGS2−/− mice. a Outline of experimental design. Bleomycin (1.5 U/kg body
weight) was administrated intratracheally on Day 1. Mice were divided into four groups (4 mice/group): bleomycin in RGS2+/+, bleomycin + PFD in RGS2
+/+, bleomycin in RGS2−/−, bleomycin + PFD in RGS2-/-. Treatment with PFD was started 1 week later and continued for 2 weeks. All mice received daily
20-min exposures to nebulized PFD solution or saline vehicle via a nose-only aerosolized delivery system. On Day 22, mice were tested in functional assays.
b Representative western blot of RGS2 protein expression in lung homogenates of RGS2+/+ and RGS2−/−mice without or with PFD treatment. c Cdyn
was measured using a Buxco FinePointe system. d The lungs were stained with trichrome to visualize collagen deposition (blue). Representative sections
from each group are shown. e Sections were scored by the Ashcroft method for overall fibrosis (scale bar = 200 μm). f Total lung collagen content was
measured by the Sirius red collagen assay. Results are expressed as μg of collagen per 100 mg of lung tissue. Data are means ± SEM (n= 4 mice). * p<
0.01, NS: not significant
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study demonstrates for the first time that RGS2 is
induced by PFD treatment and that it exhibits multiple
anti-fibrotic effects. In addition, we found that PFDtreatment or RGS2 overexpression significantly reduced
thrombin-stimulated intracellular Ca2+ signaling. Since
thrombin elevation of [Ca2+]i promotes fibroblast
proliferation and differentiation, our study provides a
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effects of RGS2.
Interestingly, animal studies suggest an important role of
RGS2 in regulation of the progression of IPF. Excess de-
position of collagen by fibroblasts in the lung and de-
creased lung compliance are hallmarks of human IPF and
of bleomycin-induced mouse pulmonary fibrosis [6, 11].
Our data showed a significant increase in collagen depos-
ition in the lungs of bleomycin-treated RGS2 knockout
(RGS2−/−) mice compared to that in bleomycin-treated
wild-type (RGS2+/+) mice. Because the accumulation of
collagen increases lung stiffness, lungs of bleomycin-
treated RGS2−/− mice exhibited much lower compliance
than lungs of similarly treated RGS2+/+ mice. The RGS2
−/− mice also exhibited a decreased survival rate compared
to RGS2+/+ mice, consistent with the high rate of mortal-
ity for IPF patients. Altogether, our study indicates that en-
dogenous RGS2 itself plays a protective role and that loss
of RGS2 augments the development of pulmonary fibrosis.
Animal studies provide further compelling support for
the importance of PFD-induced RGS2 upregulation as part
of PFD's anti-fibrotic action. PFD treatment significantly
upregulated endogenous pulmonary RGS2 expression in
RGS2+/+ mice. More importantly, PFD effectively reduced
collagen deposition in the lung following bleomycin
administration and ameliorated the bleomycin-induced
decrease in lung compliance of RGS2+/+ mice. In marked
contrast, PFD treatment had no effect in RGS2−/− mice,
indicating that upregulated RGS2 is a crucial mediator of
the anti-fibrotic effects associated with PFD treatment.
Interestingly, RGS2 has been reported to be increased in
IPF patient samples [51], which is consistent with the
notion that upregulated RGS2 functions as a potential
feed-back regulator of pulmonary fibrosis. Further investi-
gation of the relative expression levels of RGS2 in patients
with IPF following PFD treatment will be necessary to
determine the clinical importance of RGS2 upregulation in
PFD treatment of patients with IPF.
It should be noted that although western blot analyses
showed upregulation of RGS2 protein expression in lungs
of RGS2+/+ mice after PFD administration, the expression
pattern of RGS2 induction in mouse lungs is unclear. We
have performed immunohistochemical staining for RGS2
protein in paraffin-embedded mouse lung tissues. How-
ever, several RGS2 antibodies we tested showed positive
staining in RGS2−/− mice. Thus, better antibodies will be
needed to establish in which pulmonary cell types RGS2
up-regulation by PFD occurs in mice or in human patient
samples. However, RGS2 is highly expressed in pulmonary
fibroblast cells. In the bleomycin-induced pulmonary
fibrosis mouse model, RGS2−/− mice had significantly
increased pulmonary deposition of collagen compared to
RGS2+/+ mice, and this collagen is predominately
produced by differentiated pulmonary fibroblast cells,suggesting that endogenous RGS2 in pulmonary fibroblast
cells should function as an anti-fibrotic gene. Indeed, over-
expression of recombinant RGS2 or PFD treatment sig-
nificantly reduced thrombin-induced collagen production
and expression of CTGF in cultured human lung fibro-
blast cells. Interestingly, PFD treatment selectively upregu-
lates RGS2 expression without effects on the other 20 RGS
gene family members in human pulmonary fibroblast cells.
More importantly, PFD treatment also increased RGS2
expression in primary pulmonary fibroblast cells isolated
from patients with IPF. Thus, it is likely that induction of
RGS2 by PFD in pulmonary fibroblast cells contributes, at
least in part, to the anti-fibrotic effects of PFD in vivo.
Because PFD has a short half-life of only 2.5 h follow-
ing oral administration [17], the therapeutically effective
doses of PFD for human IPF and bleomycin-induced
mouse pulmonary fibrosis are very high (>30 mg/kg,
daily) [17, 18]. Such high doses can cause significant side
effects that in turn limit therapeutic effectiveness [16].
Theoretically, lowering the dose of PFD could result in
reduction of side effects. In the current study, we adminis-
tered PFD by nose-only nebulization at a dose of 0.35 mg/
kg. Our data show that PFD can be an effective anti-
fibrotic agent at much lower concentrations if the drug is
administered by inhalation directly to airways, at least in
mice. Thus developing an effective inhaled delivery form of
PFD could improve its safety and efficacy in IPF patients.
Conclusions
In conclusion, our data show that the beneficial effects
of PFD in IPF can be explained at least in part by its
ability to cause rapid RGS2 upregulation. Moreover, this
RGS2 upregulation is both necessary and sufficient for
the beneficial effects of PFD to be manifest, both in
human cells and in mice. Our data suggest that the
maintenance of intracellular RGS2 levels is of paramount
importance for preventing fibroblast proliferation and
transition to the myofibroblast phenotype that drives
IPF, adding to our understanding of IPF pathogenesis
and treatment. More importantly, our findings may help
in the design of more effective therapeutic strategies to
halt and perhaps partially reverse the progression of IPF.
Additional file
Additional file 1: Table S1. Differentially expressed genes in PFD
treatment lung fibroblast vs. control fibroblast. (DOCX 27 kb)
Abbreviations
[Ca2+]i, intracellular Ca
2+; BrdU, 5-bromo-2’-deoxyuridine; Cdyn, dynamic
compliance; CPHLF, control primary human lung fibroblast; CT, Threshold
cycle; CTGF, connective tissue growth factor; DAPI, 4’,6-diamidino-2-phenylindole;
DMEM, Dulbecco's modified eagle's medium; DPHLF, diseased primary human
lung fibroblast; F12, Ham's F-12 Nutrient Mixture; FBS, fetal bovine serum; FDA,
food and drug administration; GPCRs, G protein-coupled receptors; H&E,
hematoxylin and eosin; HFL1, human fetal lung fibroblast; IPF, idiopathic
Xie et al. Respiratory Research  (2016) 17:103 Page 13 of 14pulmonary fibrosis; PAR1, proteinase-activated receptor 1; PFD, pirfenidone; RGS2,
regulator of G-protein signaling 2; α-SMA, α-smooth muscle actin
Acknowledgments
We gratefully acknowledge Dr. Carol Feghali-Bostwick at Medical University
of South Carolina and Dr. David Siderovski at West Virginia University for
providing primary human lung fibroblasts and the original RGS2 knockout
breeding mice, respectively.
Funding
This work was supported by NIH grant R01HL116849 to Y. Tu and T.B. Casale;
R01HL097796, P01 HL114471 and P30 ES013508 to R.A. Panettieri; Nebraska
State LB595 grant to Y. Tu and P.W. Abel; and the NIH National Center for
Research Resources G20-RR024001.
Availability of data and material
All data generated or analyzed during this study are included in this
published article and its Additional file 1.
Authors’ contributions
YX, HJ, PWA, DWW, MLT, SR, RAP, TBC, and YT participated in research
design. YX, HJ, QZ, SM, PWA, and YT conducted experiments. SR, RAP, TBC
and MLT contributed materials and reagents. YX, HJ, QZ, PWA, SR, TBC, and
YT performed data analysis. YX, QZ, PWA, DWW, MLT, SR, RAP, TBC, and YT
wrote or contributed to the writing of the manuscript. All authors read and
approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
No human participants, human data or human tissue involved in studies
reported in this manuscript. All animal studies were approved by the
Institutional Animal Care and Use Committee at Creighton University.
Author details
1Department of Pharmacology, Creighton University School of Medicine,
2500 California Plaza, Omaha, NE 68178, USA. 2Department of Pharmacology
and Experimental Neuroscience, University of Nebraska Medical Center,
Omaha, NE, USA. 3Department of Biomedical Sciences, University of South
Carolina School of Medicine Greenville, Greenville, SC, USA. 4Division of
Pulmonary, Critical Care, Allergy and Sleep Medicine, University of Nebraska
Medical Center, Omaha, NE, USA. 5Clinical Discovery Unit, AstraZeneca,
Cambridge, UK. 6Pulmonary, Allergy and Critical Care Division, Airways
Biology Initiative, University of Pennsylvania, Philadelphia, PA, USA.
7Department of Internal Medicine, University of South Florida School of
Medicine, Tampa, FL 33620, USA.
Received: 26 January 2016 Accepted: 2 August 2016
References
1. King Jr T, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet. 2011;
378:1949–61.
2. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official
ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based
guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;
183:788–824.
3. Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and
prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med.
2006;174:810–6.
4. Raghu G, Chen SY, Yeh WS, Maroni B, Li Q, Lee YC, et al. Idiopathic pulmonary
fibrosis in US medicare beneficiaries aged 65 years and older: incidence,
prevalence and survival, 2001–11. Lancet Respir Med. 2014;2:566–72.
5. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol. 2008;214:
199–210.
6. Todd NW, Luzina IG, Atamas SP. Molecular and cellular mechanisms of
pulmonary fibrosis. Fibrogenesis Tissue Repair. 2012;5:11–36.7. Loomis-King H, Flaherty KR, Moore BB. Pathogenesis, current treatments and
future directions for idiopathic pulmonary fibrosis. Curr Opin Pharmacol.
2013;13:377–85.
8. Woodcock HV, Maher TM. The treatment of idiopathic pulmonary fibrosis.
F1000Prime Reports. 2014;6:16.
9. Conte E, Gili E, Fagone E, Fruciano M, Iemmolo M, Vancheri C. Effect of
pirfenidone on proliferation, TGF-β-induced myofibroblast differentiation
and fibrogenic activity of primary human lung fibroblasts. Eur J Pharm Sci.
2014;58:13–9.
10. Oku H, Shimizu T, Kawabata T, Nagira M, Hikita I, Ueyama A, et al.
Antifibrotic action of pirfenidone and prednisolone: different effects on
pulmonary cytokines and growth factors in bleomycin-induced murine
pulmonary fibrosis. Eur J Pharmacol. 2008;590:400–8.
11. Inomata M, Kamio K, Azuma A, Matsuda K, Kokuho N, Miura Y, et al.
Pirfenidone inhibits fibrocyte accumulation in the lungs in bleomycin-
induced murine pulmonary fibrosis. Respir Res. 2014;15:16–30.
12. Iyer SN, Hyde DM, Giri SN. Anti-inflammatory effect of pirfenidone in the
bleomycin-hamster model of lung inflammation. Inflammation. 2000;24:477–91.
13. Raghu G, Johnson WC, Lockhart D, Mageto Y. Treatment of idiopathic
pulmonary fibrosis with a new antifibrotic agent, pirfenidone. Am J Respir
Crit Care Med. 1999;159:1061–9.
14. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D,
et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY):
two randomised trials. Lancet. 2011;377:1760–9.
15. Poletti V, Ravaglia C, Tomassetti S. Pirfenidone for the treatment of
idiopathic pulmonary fibrosis. Expert Rev Respir Med. 2014;8:539–45.
16. Esther SK, Gillian MK. Pirfenidone: A review of its use in idiopathic
pulmonary fibrosis. Drugs. 2015;75:219–30.
17. Rubino CM, Bhavnani SM, Ambrose PG, Forrest A, Loutit JS. Effect of food
and antacids on the pharmacokinetics of pirfenidone in older healthy
adults. Pulm Pharmacol Ther. 2009;22:279–85.
18. Schaefer CJ, Ruhrmund DW, Pan L, Seiwert SD, Kossen K. Antifibrotic
activities of pirfenidone in animal Models. Eur Respir Rev. 2011;20:85–97.
19. Phan SH. The myofibroblast in pulmonary fibrosis. Chest. 2002;122:286S–9S.
20. Kendall RT, Feghali-Bostwick CA. Fibroblasts in fibrosis: novel roles and
mediators. Front Pharmacol. 2014;5:123.
21. Nakayama S, Mukae H, Sakamoto N, Kakugawa T, Yoshioka S, Soda H, et al.
Pirfenidone inhibits the expression of HSP47 in TGF-beta1-stimulated
human lung fibroblasts. Life Sci. 2008;82:210–7.
22. Heximer SP, Watson N, Linder ME, Blumer KJ, Hepler JR. RGS2/G0S8 is a
selective inhibitor of Gαq function. Proc Natl Acad Sci U S A. 2008;94:14389–93.
23. Bernstein LS, Ramineni S, Hague C, Cladman W, Chidiac P, Levey AI, et al.
RGS2 binds directly and selectively to the M1 muscarinic acetylcholine
receptor third intracellular loop to modulate Gq/11alpha signaling. J Biol
Chem. 2004;279:21248–56.
24. Ghavami A, Hunt RA, Olsen MA, Zhang J, Smith DL, Kalgaonkar S, et al.
Differential effects of regulator of G protein signaling (RGS) proteins on
serotonin 5-HT1A, 5-HT2A, and dopamine D2 receptor-mediated signaling
and adenylyl cyclase activity. Cell Signal. 2004;16:711–21.
25. Shahar I, Fireman E, Topilsky M, Grief J, Schwarz Y, Kivity S, et al. Effect of
endothelin-1 on alpha-smooth muscle actin expression and on alveolar
fibroblasts proliferation in interstitial lung diseases. Int J Immunopharmacol.
1999;21:759–75.
26. Tager AM, LaCamera P, Shea BS, Campanella GS, Selman M, Zhao Z, et al.
The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung
injury by mediating fibroblast recruitment and vascular leak. Nat Med. 2008;
14:45–54.
27. Königshoff M, Dumitrascu R, Udalov S, Amarie OV, Reiter R, Grimminger F,
et al. Increased expression of 5-hydroxytryptamine2A/B receptors in
idiopathic pulmonary fibrosis: a rationale for therapeutic intervention.
Thorax. 2010;65:949–55.
28. José RJ, Williams AE, Chambers RC. Proteinase-activated receptors in
fibroproliferative lung disease. Thorax. 2014;69:190–2.
29. Jang HS, Kim JI, Noh M, Rhee MH, Park KM. Regulator of G protein signaling
2 (RGS2) deficiency accelerates the progression of kidney fibrosis. Biochim
Biophys Acta. 1842;2014:1733–41.
30. Jiang H, Xie Y, Abel PW, Wolff DW, Toews ML, Panettieri Jr RA, et al. RGS2
repression exacerbates airway hyperresponsiveness and remodeling in
asthma. Am J Respir Cell Mol Biol. 2015;53:42–9.
31. Pilewski JM, Liu L, Henry AC, Knauer AV, Feghali-Bostwick CA. Insulin-like
growth factor binding proteins 3 and 5 are overexpressed in idiopathic
Xie et al. Respiratory Research  (2016) 17:103 Page 14 of 14pulmonary fibrosis and contribute to extracellular matrix deposition.
Am J Pathol. 2005;166:399–407.
32. Liu T, Ullenbruch M, Young Choi Y, Yu H, Ding L, Xaubet A, et al.
Telomerase and telomere length in pulmonary fibrosis. Am J Respir
Cell Mol Biol. 2013;49:260–8.
33. Cao X, Qin J, Xie Y, Khan O, Dowd F, Scofield M, et al. Regulator of G-
protein signaling 2 (RGS2) inhibits androgen-independent activation of
androgen receptor in prostate cancer cells. Oncogene. 2006;25:3719–34.
34. Mayanil CS, George D, Freilich L, Miljan EJ, Mania-Farnell B, McLone DG,
et al. Microarray analysis detects novel Pax3 downstream target genes. J
Biol Chem. 2001;276:49299–309.
35. Xie Y, Jiang H, Nguyen H, Jia S, Berro A, Panettieri Jr RA, et al. Regulator of
G protein signaling 2 is a key modulator of airway hyperresponsiveness. J
Allergy Clin Immunol. 2012;130:968–76.
36. Goncharova EA, Khavin IS, Goncharov DA, Krymskaya VP. Differential effects
of formoterol on thrombin- and PDGF-induced proliferation of human
pulmonary arterial vascular smooth muscle cells. Respir Res. 2012;13:109.
37. Bogatkevich GS, Tourkina E, Silver RM, Ludwicka-Bradley A. Thrombin
differentiates normal lung fibroblasts to a myofibroblast phenotype via the
proteolytically activated receptor-1 and a protein kinase C-dependent
pathway. J Biol Chem. 2001;276:45184–92.
38. Jara P, Calyeca J, Romero Y, Plácido L, Yu G, Kaminski N, et al. Matrix
metalloproteinase (MMP)-19-deficient fibroblasts display a profibrotic
phenotype. Am J Physiol Lung Cell Mol Physiol. 2015;308:L511–22.
39. Oliveira-Dos-Santos AJ, Matsumoto G, Snow BE, Bai D, Houston FP, Whishaw
IQ, et al. Regulation of T cell activation, anxiety, and male aggression by
RGS2. Proc Natl Acad Sci U S A. 2000;97:12272–7.
40. Hattori N, Degen JL, Sisson TH, Liu H, Moore BB, Pandrangi RG, et al.
Bleomycin-induced pulmonary fibrosis in fibrinogen-null mice. J Clin
Invest. 2000;106:1341–50.
41. Assayag EI, Beaulieu MJ, Cormier Y. Bronchodilatory and anti-inflammatory
effects of ASM-024, a nicotinic receptor ligand, developed for the treatment
of asthma. PLoS One. 2014;9:e86091.
42. Cho JY, Miller M, Baek KJ, Han JW, Nayar J, Lee SY, et al. Inhibition of airway
remodeling in IL-5-deficient mice. J Clin Invest. 2004;113:551–60.
43. Ashcroft T, Simpson JM, Timbrell V. Simple method of estimating severity
of pulmonary fibrosis on a numerical scale. J Clin Pathol. 1988;41:467–70.
44. Hübner RH, Gitter W, EI Mokhtari NE, Mathiak M, Both M, Bolte H, et al.
Standardized quantification of pulmonary fibrosis in histological samples.
Biotechniques. 2008;44:507–11.
45. Bachhuber BG, Sarembock IJ, Gimple LW, McNamara CA, Owens GK.
Thrombin-induced mitogenesis in cultured aortic smooth muscle cells
requires prolonged thrombin exposure. Am J Physiol. 1995;268(5 Pt 1):
C1141–7.
46. Ide J, Aoki T, Ishivata S, Glusa E, Strukova SM. Proteinase-activated receptor
agonists stimulate the increase in intracellular Ca2+ in cardiomyocytes and
proliferation of cardiac fibroblasts from chick embryos. Bull Exp Biol Med.
2007;144:760–3.
47. Frazier K, Williams S, Kothapalli D, Klapper H, Grotendorst GR. Stimulation of
fibroblast cell growth, matrix production, and granulation tissue formation
by connective tissue growth factor. J Invest Dermatol. 1996;107:404–11.
48. Lipson KE, Wong C, Teng Y, Spong S. CTGF is a central mediator of tissue
remodeling and fibrosis and its inhibition can reverse the process of fibrosis.
Fibrogenesis Tissue Repair. 2012;5:S1–24.
49. Chambers RC, Leoni P, Blanc-Brude OP, Wembridge DE, Laurent GJ.
Thrombin is a potent inducer of connective tissue growth factor
production via proteolytic activation of protease-activated receptor-1.
J Biol Chem. 2000;275:35584–91.
50. Kimura M, Tani K, Miyata J, Sato K, Hayashi A, Otsuka S, et al. The
significance of cathepsins, thrombin and aminopeptidase in diffuse
interstitial lung diseases. J Med Invest. 2005;52:93–100.
51. DePianto DJ, Chandriani S, Abbas AR, Jia G, N'Diaye EN, Caplazi P, et al.
Heterogeneous gene expression signatures correspond to distinct lung
pathologies and biomarkers of disease severity in idiopathic pulmonary
fibrosis. Thorax. 2015;70:48–56.•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
